Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Hold Rating from Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report published on Monday morning,Benzinga reports.

LXRX has been the subject of a number of other research reports. Leerink Partners set a $6.00 price target on shares of Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research note on Friday, October 18th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $6.00.

Lexicon Pharmaceuticals Price Performance

LXRX stock opened at $0.83 on Monday. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The company’s 50-day moving average is $1.18 and its 200-day moving average is $1.56. The stock has a market capitalization of $204.38 million, a PE ratio of -1.11 and a beta of 1.07. Lexicon Pharmaceuticals has a 1 year low of $0.62 and a 1 year high of $3.73.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.01). The firm had revenue of $1.75 million during the quarter, compared to the consensus estimate of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. During the same quarter in the previous year, the company posted ($0.21) EPS. Equities research analysts expect that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Barclays PLC grew its position in Lexicon Pharmaceuticals by 391.6% in the 3rd quarter. Barclays PLC now owns 193,873 shares of the biopharmaceutical company’s stock worth $304,000 after purchasing an additional 154,436 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Lexicon Pharmaceuticals by 8.4% in the third quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company’s stock valued at $5,534,000 after acquiring an additional 273,436 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Lexicon Pharmaceuticals during the third quarter valued at approximately $126,000. State Street Corp lifted its holdings in Lexicon Pharmaceuticals by 6.8% during the third quarter. State Street Corp now owns 2,471,215 shares of the biopharmaceutical company’s stock worth $3,880,000 after acquiring an additional 157,738 shares during the period. Finally, Atom Investors LP bought a new stake in Lexicon Pharmaceuticals during the third quarter worth $122,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.